EuropeanHIVHep
Meeting category
Date(s)
22 May 2019 - 24 May 2019
Location
Rome, Italy
Organizer

European Meeting on HIV & Hepatitis 2019

Related Enduring Materials

Enduring Materials
Program

Day 1 - Wednesday, 22 May

Opening session -
Chairs
Francesca Ceccherini-Silberstein, PhD
University of Rome “Tor Vergata”, Italy
Roger Paredes, MD, PhD
Hospital Germans Trias & IrsiCaixa AIDS Research Institute, Spain
09:00 CEST
Tribute to Andrea De Luca and Ricardo Camacho
09:15 CEST
Andrea De Luca Lecture: The top 10 important observations of the last year affecting clinical management
09:45 CEST
Resistance to integrase inhibitors
Anne-Geneviève Marcelin, MD
Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France
Session 1: The role of the reservoir on clinical decision making -
Chairs
Jan Albert, MD, PhD
Karolinska Institute, Stockholm, Sweden
placeholder3
Rolf Kaiser, PhD
University of Cologne, Germany
10:45 CEST
How to measure the reservoir
Buzon Maria Jose
María José Buzón, PhD
Vall d'Hebron Research Institute, Spain
11.15 CEST
How does the reservoir influence the clinician's decisions
Carlo Federico Perno, MD, PhD
Pediatric Hospital Bambino Gesù, Italy
Special Session: Genetic Barrier – Role in HIV Treatment Decision -
Chair
Charles Boucher, MD, PhD
Erasmus Medical Center, The Netherlands
12:00 CEST
Genetic Barrier, Basic Principles
Jonathan Schapiro, MD
National Hemophilia Center, Sheba Medical Center, Israel
12:20 CEST
Genetic Barrier and Reduced Drug Regimens
Quercia, Romina
Romina Quercia, MD, PhD
ViiV Healthcare, United Kingdom
12:40 CEST
Genetic Barrier – Clinical Cases
Roger Paredes, MD, PhD
Hospital Germans Trias & IrsiCaixa AIDS Research Institute, Spain
Session 2: Role of STI management in HIV prevention -
Chairs
placeholder3
David van de Vijver
-
Gary Rubin, MD, MCFP, AAHIVS
University of Toronto, Canada
14:00 CEST
New approaches to STI management
Whitlock, Gary
Gary Whitlock, MD
Dean Street Clinic, Chelsea & Westminster Hospital United Kingdom
14.20 CEST
Interplay between PrEP and STI
Bébéar, Cecile
Cécile Bébéar, MD, PhD
University of Bordeaux, France
Abstract - driven presentations - 14.35
14.35 CEST
First results after 52 weeks of informal PrEP use in a cohort of MSM in Southern Spain.
Manuel Reiriz Rojas
Spain
14:50 CEST
European surveillance of HIV drug resistance to NRTI, NNRTI and INSTI in newly diagnosed individuals using next-generation sequencing.
Carole Seguin-Devaux
France
15:15 CEST
Molecular analysis suggests post-migration HIV-1 acquisition among migrants in Paris, France.
Evangelia Kostaki
Greece
15:30 CEST
Trends of transmitted and acquired hiv-1 drug resistance in patients followed in portuguese hospitals between 2001 and 2017
Marta Pingarilho
Portugal
Session 3: Clinical management of HIV - related abstracts -
Chairs
Roger Paredes, MD, PhD
Hospital Germans Trias & IrsiCaixa AIDS Research Institute, Spain
placeholder3
Anne-Mieke Vandamme
-
16:40 CEST
Remembering Ricardo Camacho: HIV-2 Diagnostics, therapy and resistance testing
Rolf Kaiser, PhD
University of Cologne, Germany
16:55 CEST
Seminal HIV-1 RNA and drug concentrations in DTG+3TC dual therapy (ANRS167 Lamidol)
Charlotte Charpentier
France
17:10 CEST
Predicting 2-drug antiretroviral regimen efficacy by genotypic susceptibility score: results from a cohort study
Barbara Rossetti
Italy
17:25 CEST
High prevalence of the integrase resistance associated accessory mutation L74I in the Russian Federation
Alina Kirichenko
Russia
17:40 CEST
Fostemsavir (FTR) Week 48 efficacy and evaluation of treatment emergent substitutions in the BRIGHTE study
Max Lataillade
USA
17:55 CEST
Epidemiological study of Doravirine associated resistance mutations in HIV-1-infected antiretroviral-experienced patients from two large databases in France and Italy
Anne-Geneviéve Marcelin
France

Day 2 - Thursday, 23 May

Session 4: What's in the pipeline? -
Chairs
Jonathan Schapiro, MD
National Hemophilia Center, Sheba Medical Center, Israel
Anne-Geneviève Marcelin, MD
Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France
08.30 CEST
Presentations from scientists from the industry
Garges, Harmony
Harmony P. Garges, MD, MPH
Vice President and Head, Global Medical Affairs, ViiV Healthcare, USA
Stamm, Luisa
Luisa Stamm, MD, PhD
Executive Director, HIV and Emerging Viral Infections, Gilead Sciences, USA
Schuitemaker, Hanneke
Hanneke Schuitemaker, PhD
Vice President, Head Viral Vaccine Discovery and Translational Medicine, Janssen, The Netherlands
Kathleen Squires, MD
Global Director Scientific Affairs - ID/HIV, Merck, United States
Special Session: Clinical considerations in choosing first-line therapy -
Chair
Carlo Federico Perno, MD, PhD
Pediatric Hospital Bambino Gesù, Italy
11:15 CEST
Welcome and introduction
Carlo Federico Perno
Carlo Federico Perno, MD, PhD
University of Milan, Italy
11:20 CEST
Same day treatment initiation
placeholder3
Tristan Barber, MA MRCP
Royal Free Hospital, London, United Kingdom
11:40 CEST
First line therapies: implications for long term resistance
Anne-Geneviève Marcelin, MD
Pitié-Salpêtrière Hospital, Sorbonne Université, Paris, France
12:00 CEST
Clinical case
placeholder3
Rocio Montejano Sanchez, MD
Hospital Universitario La Paz, Madrid, Spain
Session 5: Management of viral hepatitis I -
Chairs
Francesca Ceccherini-Silberstein, PhD
University of Rome “Tor Vergata”, Italy
Carlo Perno
-
13:15 CEST
Novel compounds for HBV therapy
Pietro Lampertico, MD, PhD
University of Milan, Italy
13.45 CEST
Novel markers on HBV / HDV co-infection
Svicher, Valentina
Valentina Svicher, PhD
University of Rome Tor Vergata, Italy
14:15 CEST
Abstract-driven presentations
The integration of Hepatitis B virus in relevant regions of human genome is a common event in the setting of HBeAg negative chronic infection despite limited liver disease: implications for an altered cell metabolism
Romina Salpini, Italy
The transmission dynamics of acute HCV infections in HIV-positive men who have sex with men in the Netherlands is suitable for targeted risk reduction strategies
Stephanie Popping, the Netherlands
Session 6: Management of viral hepatitis II - 15.45
15.45 CEST
Clinical relevance of HCV rare subtypes
Slim Fourati, MD, PhD
Henri Mondor Hospital, Paris-Est University, France
16:15 CEST
Abstract-driven presentations
Clinical and virological characteristics of patients with chronic hepatitis C and failure to a Glecaprevir and Pibrentasvir (G/P) treatment in real world
Federico Garcia, Spain
Retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen after performing a genotypic resistance test: the Italian Vironet C real life experience
Velia Chiara Di Maio
Specific NS5A polymorphisms correlate with hepatocellular carcinoma in cirrhotic patients infected with HCV genotype 1b
Mohammad Altkhatib

Day 3 - Friday, 24 May

Session 7: Clinical management challenges - 08:30
08:30 CEST
The new patient - with what & when
Reiss, Peter
Peter Reiss, MD, PhD
UMC Amsterdam, The Netherlands
09:00 CEST
The aging patient
Eugenia, Negredo
Eugenia Negredo, PhD
Hospital Universitari Germans Trias i Pujol, Badalona, Spain
09:30 CEST
The pregnant woman - update
Mandelbrot, Laurent
Laurent Mandelbrot, MD
Hôpitaux Universitaires Paris Nord, Paris, France
Session 8: Abstracts - part I -
Chair
placeholder3
Leon Kostrikis
-
10:00 CEST
Longitudinal analysis of proviral HIV-DNA
Eva Heger
Germany
10:15 CEST
Single genome sequencing of near full-length HIV-1 RNA
Laura Hebberecht
Belgium
Session 9: Abstracts - part II - 11:00
11:00 CEST
Maraviroc as a Latency Reversing Agent in cell line models
Filippo Dragoni
Italy
11:15 CEST
Viral Dynamics During Suppressive ART - Towards HIV-1 Elimination From Reservoirs
Thomas Klimkait
Switzerland
Session 10: Progress in cure / elimination approaches -
Chair
Dimitrios Paraskevis, PhD
National and Kapodistrian University of Athens, Greece
Carlo Perno
-
11:30 CEST
Update on the London patient
Ravindra Gupta
Ravindra Gupta, MD, PhD
University of Cambridge, United Kingdom
11:45 CEST
Update on HIV cure research
Linos Vandekerckhove
Linos Vandekerckhove, MD, PhD
University of Gent, Belgium
12:15 CEST
Hepatitis C elimination research
Angelos Hatzakis, MD, PhD, MSc
Athens University Medical School, Greece
12:45 CEST
Perspectives in HBV cure research
Fabien Zoulim, MD, PhD
Lyon I University / Hospices Civils de Lyon / INSERM, France
13:30 CEST
Ricardo Camacho Award ceremony and closure of the meeting
Language